Study of QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2017
At a glance
- Drugs QR 313 (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions; First in man
- 19 Sep 2017 According to a ProQR media release, clinical data from this program will be available in 2018.
- 13 Dec 2016 New trial record
- 14 Nov 2016 According to a ProQR media release, company plans to start this study in 2018.